COMP <GO>
CPHI vs JNJ // EV/EBITDA & P/E VALUATION
China Pharma Holdings Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CPHI 0
— JNJ 10
■ METRIC PARITY
LAST: $0.65 (+4.84%) • MKT CAP: $28.0M
valuation
—
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CPHI VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CPHI | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | -3.20% | 67.90% | -71.10 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.40% | 25.50% | -36.90 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.32% | 2.97% | -2.65 | JNJ | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -8.50% | 6.00% | -14.50 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.59 | -5.39 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.2 | 62.1 | -21.93 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $28.0M | $662.49B | -$662.46B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CPHI REV | JNJ REV | CPHI GROSS % | JNJ GROSS % | CPHI FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.1M | $94.19B | -3.2% | 67.9% | $88.9K | $19.70B |
| FY 2024 | $4.5M | $88.82B | -43.8% | 69.1% | -$444.5K | $19.84B |
| FY 2023 | $7.0M | $85.16B | — | — | -$699.7K | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CPHI // BETA —
JNJ // BETA 1.08